Cargando…

Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil

This study reports the first case of an innovative drop-on-powder (DoP) three-dimensional (3D) printing technology to produce oral tablets (diameters of 10 mm and 13 mm) loaded with an anticancer model drug, 5-fluorouracil (FLU). For this study, a composition of the powder carrier containing CaSO(4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Kejing, Tan, Deck K., Nokhodchi, Ali, Maniruzzaman, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523964/
https://www.ncbi.nlm.nih.gov/pubmed/30939760
http://dx.doi.org/10.3390/pharmaceutics11040150
_version_ 1783419456581533696
author Shi, Kejing
Tan, Deck K.
Nokhodchi, Ali
Maniruzzaman, Mohammed
author_facet Shi, Kejing
Tan, Deck K.
Nokhodchi, Ali
Maniruzzaman, Mohammed
author_sort Shi, Kejing
collection PubMed
description This study reports the first case of an innovative drop-on-powder (DoP) three-dimensional (3D) printing technology to produce oral tablets (diameters of 10 mm and 13 mm) loaded with an anticancer model drug, 5-fluorouracil (FLU). For this study, a composition of the powder carrier containing CaSO(4) hydrates, vinyl polymer, and carbohydrate was used as the matrix former, whereas 2-pyrrolidone with a viscosity like water was used as a binding liquid or inkjet ink. All tablets were printed using a commercial ZCorp 3D printer with modification. The resultant tablets were subject to coating with various polymeric solutions containing the drug. The composition of the polymeric solutions was adjusted at drug: polymer(s) 1:1 (w/w) ratio. Either Soluplus(®) (SOL) alone or in combination with polyethylene glycol (PEG) was used to develop the coating solution of 2.5% (w/v) concentration. The particle size analysis, flow test, and particle morphology studies revealed mono-modal narrow size distribution, good flow properties, and porous loosely bound texture (of the tablets), respectively. Moreover, the advanced application of the fluorescence microscopy showed a homogenous distribution of the drug throughout the surface of the 3D printed tablets. The in vitro dissolution studies showed that the tablet compositions, dimensions, and the coating solution compositions influenced the release of the drug from the tablets. It can be concluded that our innovative DoP 3D printing technology can be used to fabricate personalized dosage forms containing optimized drug content with high accuracy and shape fidelity. This is particularly suitable for those drugs that are highly unstable in thermal processing and cannot withstand the heat treatment, such as in fused deposition modeling (FDM) 3D printing.
format Online
Article
Text
id pubmed-6523964
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65239642019-06-04 Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil Shi, Kejing Tan, Deck K. Nokhodchi, Ali Maniruzzaman, Mohammed Pharmaceutics Communication This study reports the first case of an innovative drop-on-powder (DoP) three-dimensional (3D) printing technology to produce oral tablets (diameters of 10 mm and 13 mm) loaded with an anticancer model drug, 5-fluorouracil (FLU). For this study, a composition of the powder carrier containing CaSO(4) hydrates, vinyl polymer, and carbohydrate was used as the matrix former, whereas 2-pyrrolidone with a viscosity like water was used as a binding liquid or inkjet ink. All tablets were printed using a commercial ZCorp 3D printer with modification. The resultant tablets were subject to coating with various polymeric solutions containing the drug. The composition of the polymeric solutions was adjusted at drug: polymer(s) 1:1 (w/w) ratio. Either Soluplus(®) (SOL) alone or in combination with polyethylene glycol (PEG) was used to develop the coating solution of 2.5% (w/v) concentration. The particle size analysis, flow test, and particle morphology studies revealed mono-modal narrow size distribution, good flow properties, and porous loosely bound texture (of the tablets), respectively. Moreover, the advanced application of the fluorescence microscopy showed a homogenous distribution of the drug throughout the surface of the 3D printed tablets. The in vitro dissolution studies showed that the tablet compositions, dimensions, and the coating solution compositions influenced the release of the drug from the tablets. It can be concluded that our innovative DoP 3D printing technology can be used to fabricate personalized dosage forms containing optimized drug content with high accuracy and shape fidelity. This is particularly suitable for those drugs that are highly unstable in thermal processing and cannot withstand the heat treatment, such as in fused deposition modeling (FDM) 3D printing. MDPI 2019-04-01 /pmc/articles/PMC6523964/ /pubmed/30939760 http://dx.doi.org/10.3390/pharmaceutics11040150 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Shi, Kejing
Tan, Deck K.
Nokhodchi, Ali
Maniruzzaman, Mohammed
Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil
title Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil
title_full Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil
title_fullStr Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil
title_full_unstemmed Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil
title_short Drop-On-Powder 3D Printing of Tablets with an Anti-Cancer Drug, 5-Fluorouracil
title_sort drop-on-powder 3d printing of tablets with an anti-cancer drug, 5-fluorouracil
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523964/
https://www.ncbi.nlm.nih.gov/pubmed/30939760
http://dx.doi.org/10.3390/pharmaceutics11040150
work_keys_str_mv AT shikejing droponpowder3dprintingoftabletswithananticancerdrug5fluorouracil
AT tandeckk droponpowder3dprintingoftabletswithananticancerdrug5fluorouracil
AT nokhodchiali droponpowder3dprintingoftabletswithananticancerdrug5fluorouracil
AT maniruzzamanmohammed droponpowder3dprintingoftabletswithananticancerdrug5fluorouracil